These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4012308)

  • 1. Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog.
    Sikic BI; Ehsan MN; Harker WG; Friend NF; Brown BW; Newman RA; Hacker MP; Acton EM
    Science; 1985 Jun; 228(4707):1544-6. PubMed ID: 4012308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: comparative in vitro potency against leukemia and bone marrow cells.
    Beckman RA; McFall PJ; Sikic BI; Smith SD
    J Natl Cancer Inst; 1988 May; 80(5):361-5. PubMed ID: 3357201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin and doxorubicin on the survival, DNA integrity, and nucleolar morphology of human leukemia cells in vitro.
    Wassermann K; Zwelling LA; Mullins TD; Silberman LE; Andersson BS; Bakic M; Acton EM; Newman RA
    Cancer Res; 1986 Aug; 46(8):4041-6. PubMed ID: 3731072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin and doxorubicin in nude mice bearing human tumour xenografts.
    Ford CH; Richardson VJ; Pushpanathan C; Ali SK
    Anticancer Res; 1991; 11(5):1855-62. PubMed ID: 1768056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin.
    Pinna A; Agen C; Di Paolo A; Innocenti F; Nardini D; Danesi R; Del Tacca M
    J Environ Pathol Toxicol Oncol; 1994; 13(1):25-31. PubMed ID: 7823290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.
    Ganzina F
    Cancer Treat Rev; 1983 Mar; 10(1):1-22. PubMed ID: 6342772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells.
    Scudder SA; Brown JM; Sikic BI
    J Natl Cancer Inst; 1988 Oct; 80(16):1294-8. PubMed ID: 3172256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.
    Lau DH; Ross KL; Sikic BI
    Cancer Res; 1990 Jul; 50(13):4056-60. PubMed ID: 2162251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs.
    Lehotay DC; Levey BA; Levey GS
    Biomed Pharmacother; 1983; 37(7):312-6. PubMed ID: 6141818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
    van Acker FA; Boven E; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
    Clin Cancer Res; 2001 May; 7(5):1378-84. PubMed ID: 11350909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin.
    Lau DH; Durán GE; Sikic BI
    J Natl Cancer Inst; 1992 Oct; 84(20):1587-92. PubMed ID: 1404452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin).
    Ryu JS; Lee HS; Hong YS; Lee JJ; Sohn UD; Kim TY
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):811-8. PubMed ID: 16175393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin in sensitive and resistant L5178Y lymphoblasts in vitro.
    Begleiter A; Leith MK; Johnston JB
    Cancer Res; 1994 Jan; 54(2):482-6. PubMed ID: 8275485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3'-Deamino-3'-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity.
    Danesi R; Agen C; Grandi M; Nardini V; Bevilacqua G; Del Tacca M
    Eur J Cancer; 1993; 29A(11):1560-5. PubMed ID: 8217363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.
    Qiao X; van der Zanden SY; Wander DPA; Borràs DM; Song JY; Li X; van Duikeren S; van Gils N; Rutten A; van Herwaarden T; van Tellingen O; Giacomelli E; Bellin M; Orlova V; Tertoolen LGJ; Gerhardt S; Akkermans JJ; Bakker JM; Zuur CL; Pang B; Smits AM; Mummery CL; Smit L; Arens R; Li J; Overkleeft HS; Neefjes J
    Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15182-15192. PubMed ID: 32554494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(2-hydroxyethyl)doxorubicin from hydrolysis of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin.
    Acton EM; Tong GL; Smith TH; Taylor DL; Streeter DG; Peters JH; Gordon GR; Filppi JA; Wolgemuth RL; Giuliani FC
    J Med Chem; 1986 Oct; 29(10):2120-2. PubMed ID: 3761328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.